Ostodron 150 Tablet contains Ibandronic Acid 150mg, a bisphosphonate that helps prevent bone loss, increases bone density, and reduces the risk of fractures in patients with osteoporosis, especially postmenopausal women and those on long-term corticosteroid therapy.
The tablet works by inhibiting bone resorption, strengthening skeletal structure, and improving calcium retention. Regular use supports musculoskeletal health and helps maintain strong bones.
Ostodron 150 Tablet belongs to the orthopedic and bone health segment, commonly prescribed by endocrinologists, orthopedists, and general physicians for bone loss prevention and management.
For PCD pharma franchise partners, wholesalers, and exporters, Ostodron 150 Tablet offers a high-demand market opportunity. It is available for bulk supply, monopoly-based PCD franchise, third-party manufacturing, institutional distribution, and export, ensuring consistent demand and profitable business growth.